StockNews.AI
RLAY
StockNews.AI
181 days

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025

1. Relay Therapeutics will report Q4 and full year 2024 results soon. 2. The company focuses on precision medicine and innovative drug discovery. 3. Relay's Dynamo® platform targets difficult-to-address protein targets. 4. Their focus includes oncology and genetic disease indications. 5. Investors will consider upcoming financial results for market sentiment.

Earnings
-1.68%Current Return
VS
-0.39%S&P 500
$4.1602/19 04:12 PM EDTEvent Start
$4.0902/20 10:53 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

Upcoming financial results could provide insights but are generally expected.

How important is it?

Earnings reports typically influence stock evaluations, increasing relevance to investors.

Why Short Term?

The report could temporarily impact stock price based on results and expectations.

Related Companies

RLAY
February 19, 2025 16:05 ET  | Source: Relay Therapeutics, Inc. CAMBRIDGE, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report fourth quarter and full year 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, February 26, 2025. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter. Contact:Pete Rahmerprahmer@relaytx.com Media:Dan Budwick1AB973-271-6085dan@1abmedia.com

Related News